| Literature DB >> 24427451 |
Johan Stedt1, Jonas Bonnedahl2, Jorge Hernandez1, Barry J McMahon3, Badrul Hasan4, Björn Olsen4, Mirva Drobni4, Jonas Waldenström1.
Abstract
BACKGROUND: The prevalence of antibiotic resistant faecal indicator bacteria from humans and food production animals has increased over the last decades. In Europe, resistance levels in Escherichia coli from these sources show a south-to-north gradient, with more widespread resistance in the Mediterranean region compared to northern Europe. Recent studies show that resistance levels can be high also in wildlife, but it is unknown to what extent resistance levels in nature conform to the patterns observed in human-associated bacteria.Entities:
Keywords: Antibiotic resistance; Escherichia Coli; antibiotics; birds; gulls; wildlife
Year: 2014 PMID: 24427451 PMCID: PMC3889177 DOI: 10.3402/iee.v4.21565
Source DB: PubMed Journal: Infect Ecol Epidemiol ISSN: 2000-8686
Summary of sampling sites, sampled gull species, number of collected samples, isolated E. coli included in the study and a description of the sites sampled.
| Country | Location | Species | Samples | Description |
|---|---|---|---|---|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The proportion of E. coli isolates with resistance to one or more antibiotics on each sampling site.
| 0 | ≥1 | ≥2 | ≥3 | ≥4 | ≥5 | ≥6 | ≥7 | 8 | |
|---|---|---|---|---|---|---|---|---|---|
| Denmark | 91.7 | 8.3 | 5.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| England | 55.9 | 44.1 | 25 | 13.2 | 7.4 | 1.5 | 2.9 | 1.5 | 0.0 |
| Ireland | 88.4 | 11.6 | 1.9 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Latvia, Daugava | 58.0 | 42.0 | 31.7 | 26.3 | 18.7 | 12.5 | 40.0 | 0.4 | 0.0 |
| Latvia, Kaltene | 96.7 | 3.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Netherlands, Borsele | 75.5 | 24.5 | 10.9 | 7.0 | 3.5 | 1.7 | 0.0 | 0.0 | 0.0 |
| Netherlands, Rotterdam | 83.3 | 16.7 | 9.2 | 7.4 | 5.2 | 2.6 | 2.2 | 0.4 | 0.0 |
| Poland | 78.7 | 21.3 | 4.7 | 2.6 | 1.7 | 0.9 | 0.0 | 0.0 | 0.0 |
| Portugal, Lagos | 76.4 | 23.6 | 18.3 | 11.0 | 9.4 | 7.3 | 2.1 | 0.0 | 0.0 |
| Portugal, Portimao | 69.1 | 30.9 | 24.7 | 16.0 | 9.9 | 3.7 | 1.2 | 0.0 | 0.0 |
| Spain, Emporda | 39.3 | 60.7 | 40.5 | 28.6 | 20.2 | 10.7 | 2.4 | 1.2 | 0.0 |
| Spain, Mazzaron | 32.9 | 67.1 | 57.3 | 45.3 | 31.5 | 16.9 | 5.8 | 0.9 | 0.0 |
| Spain, Malaga | 50.0 | 50.0 | 42.5 | 35.0 | 27.5 | 15.0 | 7.5 | 0.8 | 0.0 |
| Sweden | 82.3 | 17.7 | 9.7 | 6.9 | 4.0 | 3.4 | 1.1 | 0.0 | 0.0 |
Fig. 1Geographical variation in gull E. coli resistance levels in nine different European countries. Dots represent sampling sites in each country, and the bar plots show average resistance levels (%) to each of the analysed antibiotics. The antibiotics, from left to the right: nalidixic acid (NA), streptomycin (S), tetracycline (TE), ampicillin (AMP), chloramphenicol (C), cefadroxil (CFR), tigecycline (TGC), nitrofurantoin (N), mecillinam (MEL) and trimethoprim/sulfamethoxazole (SXT). The bar plot from Spain is enlarged to indicate the scale used.
Percentage of isolated gull E. coli with resistance to each of the tested antibiotic separated per sampling site.
| Nalidixic acid | Streptomycin | Tetracykline | Ampicillin | Chloramphenicol | Cefadroxil | Tigecycline | Nitrofurantoin | Mecillinam | Trimethoprim/sulfamethoxazole | |
|---|---|---|---|---|---|---|---|---|---|---|
| Denmark | 0.0 | 3.1 | 1.0 | 6.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.1 |
| England | 5.9 | 10.3 | 27.9 | 33.8 | 2.9 | 1.5 | 0.0 | 0.0 | 1.5 | 10.3 |
| Ireland | 0.8 | 0.8 | 2.7 | 1.9 | 0.4 | 0.8 | 0.0 | 0.4 | 0.4 | 0.8 |
| Latvia, Daugava | 21.4 | 21.4 | 29.0 | 29.9 | 10.3 | 1.8 | 0.0 | 4.0 | 0.4 | 17.4 |
| Latvia, Kaltene | 0.0 | 1.7 | 0.0 | 1.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Netherlands, Borsele | 2.2 | 9.6 | 15.3 | 13.5 | 0.4 | 0.4 | 0.0 | 0.0 | 0.4 | 5.7 |
| Netherlands, Rotterdam | 5.7 | 7.9 | 12.3 | 8.8 | 2.6 | 0.9 | 0.0 | 0.0 | 0.0 | 5.7 |
| Poland | 3.4 | 3.4 | 6.0 | 6.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.9 |
| Portugal, Lagos | 12.0 | 9.4 | 18.3 | 15.7 | 3.7 | 3.1 | 0.0 | 1.0 | 0.0 | 8.4 |
| Portugal, Portimao | 8.6 | 14.8 | 25.9 | 17.3 | 4.9 | 0.0 | 0.0 | 0.0 | 2.5 | 12.3 |
| Spain, Emporda | 32.1 | 27.4 | 34.5 | 39.3 | 10.7 | 3.6 | 0.0 | 0.0 | 1.2 | 15.5 |
| Spain, Mazzaron | 36.9 | 28 | 52 | 44.9 | 20.4 | 11.1 | 0 | 1.3 | 0.4 | 29.8 |
| Spain, Malaga | 30.8 | 21.7 | 37.5 | 42.5 | 16.7 | 10.8 | 3.3 | 0.0 | 0.8 | 16.6 |
| Sweden | 2.9 | 6.9 | 10.3 | 13.7 | 2.9 | 2.3 | 0.0 | 0.0 | 0.0 | 4.6 |
Fig. 2Differences in antibiotic resistance levels between two sampling sites in Latvia. Bars shows the percentage of isolated E. coli with resistance to each tested antibiotic.
All combinations of recognised phenotypes with multiresistance (≥3 antibiotics). Illustrating the diversity of multiresistant phenotypes among the tested E. coli from the nine sampled countries across Europe.
| Poland | Sweden | Latvia | Ireland | England | Netherlands | Spain | Portugal | Denmark | Total | |
|---|---|---|---|---|---|---|---|---|---|---|
| NA-S-TE | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 4 |
| NA-S-AMP | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 4 |
| NA-S-C | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| NA-TE-AMP | 0 | 1 | 5 | 0 | 0 | 3 | 12 | 1 | 0 | 22 |
| NA-TE-C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| NA-TE-F | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| NA-TE-SXT | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| NA-AMP-CFR | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 3 |
| NA-AMP-SXT | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 3 |
| TE-AMP-C | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| TE-AMP-CFR | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 4 |
| TE-AMP-MEL | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 3 |
| TE-AMP-SXT | 0 | 1 | 0 | 0 | 2 | 1 | 2 | 0 | 0 | 6 |
| TE-C-SXT | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 5 |
| S-AMP-SXT | 1 | 0 | 3 | 0 | 1 | 0 | 1 | 0 | 0 | 6 |
| S-TE-AMP | 1 | 1 | 0 | 0 | 0 | 7 | 8 | 0 | 0 | 17 |
| S-TE-C | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| S-TE-SXT | 0 | 0 | 1 | 0 | 0 | 1 | 8 | 0 | 0 | 10 |
| NA-S-TE-AMP | 3 | 0 | 3 | 0 | 0 | 0 | 8 | 1 | 0 | 15 |
| NA-S-TE-F | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| NA-S-TE-SXT | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| NA-S-AMP-SXT | 0 | 0 | 1 | 0 | 0 | 1 | 4 | 0 | 0 | 6 |
| NA-TE-C-SXT | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| NA-TE-AMP-SXT | 0 | 0 | 0 | 0 | 0 | 1 | 7 | 0 | 0 | 8 |
| NA-TE-AMP-C | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 2 | 0 | 12 |
| NA-TE-AMP-CFR | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| NA-TE-AMP-MEL | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| NA-AMP-C-CFR | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| NA-AMP-C-F | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| NA-AMP-C-SXT | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| S-TE-AMP-CFR | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| S-TE-AMP-C | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
| S-TE-AMP-SXT | 0 | 1 | 7 | 0 | 2 | 8 | 12 | 1 | 0 | 31 |
| S-TE-C-SXT | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 4 |
| S-AMP-MEL-SXT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| TE-AMP-C-CFR | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| TE-AMP-C-SXT | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 4 |
| NA-S-TE-AMP-C | 0 | 0 | 1 | 0 | 0 | 0 | 4 | 0 | 0 | 5 |
| NA-S-TE-AMP-CFR | 0 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 4 |
| NA-S-TE-AMP-F | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| NA-S-TE-AMP-SXT | 1 | 1 | 5 | 0 | 0 | 3 | 12 | 10 | 0 | 32 |
| NA-S-AMP-F-SXT | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| NA-TE-AMP-CFR-SXT | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 3 |
| NA-TE-AMP-C-CFR | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 1 | 0 | 11 |
| NA-TE-AMP-C-F | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| NA-TE-AMP-C-SXT | 0 | 0 | 5 | 0 | 0 | 1 | 1 | 0 | 0 | 7 |
| NA-TE-C-F-SXT | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| S-TE-AMP-C-SXT | 0 | 0 | 1 | 0 | 0 | 0 | 6 | 0 | 0 | 7 |
| S-TE-AMP-CFR-SXT | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
| S-TE-AMP-MEL-SXT | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| S-TE-AMP-F-SXT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| TE-AMP-C-CFR-SXT | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| NA-S-TE-AMP-C-SXT | 0 | 2 | 7 | 0 | 1 | 4 | 13 | 3 | 0 | 30 |
| NA-S-TE-AMP-F-SXT | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| NA-S-TE-AMP-CFR-SXR | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 0 | 5 |
| NA-S-TE-AMP-C-F-SXT | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| NA-S-TE-AMP-C-CFR | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 3 |
| NA-S-AMP-C-CFR-SXT | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| NA-S-TE-AMP-C-CFR-SXT | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 0 | 5 |
NA, nalidixic acid; S, streptomycin; TE, tetracycline; AMP, ampicillin; C, chloramphenicol; CFR, cefadroxil; TGC, tigecycline; N, nitrofurantoin; MEL, mecillinam and SXT, trimethoprim/sulfamethoxazole.